Bio-Techne Corp (TECH) is experiencing shifts in its market position, with boosts in stock holdings by Squarepoint Ops LLC, The Manufacturers Life Insurance Company, and MBB Public Markets I LLC, but decreases by Toronto Dominion Bank, Marshall Wace LLP, Select Equity Group LP, Susquehanna Portfolio Strategies LLC, and STX Topco Ltd. The company recently released its Q4 FY2024 earnings, with GAAP EPS of $0.25, slightly missing revenue targets but meeting profit estimates. A series of announcements emphasized Bio-Techne's commitment to innovation, strategic investments and partnerships, such as backing Spear Bio in a $45-million Series A funding, a new distribution agreement with Thermo Fisher Scientific, a collaboration with Nikon Instruments, and a sizable investment in Wilson Wolf Manufacturing. Furthermore, the company unveiled a new high-throughput Western system and the MauriceFlex system, while surpassing 10,000 peer-reviewed publications citing RNAscope technology, attributing this to the company's proprietary technology. The company recently completed acquisitions of Lunaphore and Namocell, and announced the opening of new facilities in Canada and Ireland.
Bio-Techne Corp TECH News Analytics from Thu, 07 Jun 2018 07:00:00 GMT to Fri, 04 Oct 2024 08:16:11 GMT - Rating 6 - Innovation 7 - Information 8 - Rumor -2
